Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).-Reference-Cited by-同舟云学术

Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).

Published:2016-05-20 Issue:15_suppl Volume:34 Page:TPS3103-TPS3103
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Abou-Alfa Ghassan K.¹,Sangro Bruno²,Morse Michael³,Zhu Andrew X.⁴,Kim Richard D.⁵,Cheng Ann-Lii⁶,Kudo Masatoshi⁷,Kang Yoon-Koo⁸,Chan Stephen L.⁹,Antal Joyce¹⁰,Boice Jillian¹⁰,Xiao Feng¹⁰,Morris Shannon R.¹⁰,Bendell Johanna¹¹,

Affiliation:

1. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY;

2. Clínica Universidad de Navarra, IDISNA-CIBEREHD, Pamplona, Spain;

3. Duke University Medical Center, Durham, NC;

4. Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA;

5. H. Lee Moffit Cancer Center, Tampa, FL;

6. National Taiwan University Hospital, Taipei, Taiwan;

7. Kinki University School of Medicine, Osakasayama-shi, Osaka, Japan;

8. Asan Medical Center, University of Ulsan, Seoul, South Korea;

9. The Chinese University of Hong Kong, Hong Kong, Hong Kong;

10. MedImmune, Gaithersburg, MD;

11. Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN;